Key result
Impella 5.5 successfully bridges refractory cardiogenic shock and cardiointestinal syndrome to definitive heart failure therapy.
Why the study?
Patients with advanced heart failure often develop end-organ dysfunction including gastrointestinal sequelae, and early mechanical circulatory support may aid recovery in acute cardiogenic shock.
Case Report (n=2)
Answers are grounded in this paper and cite their sources.
Impella 5.5 can serve as an effective bridge to decision in patients with refractory cardiogenic shock and cardiointestinal syndrome, allowing end-organ recovery prior to definitive heart failure therapies.
Patients with advanced heart failure require multi-system management as a majority succumb to end-organ dysfunction, including gastrointestinal sequelae. Temporizing measures, such as early mechanical circulatory support, can assist in the recovery of patients with acute cardiogenic shock. The temporary support can improve patient characteristics to enable future definitive heart failure therapies such as durable left ventricular assist devices and orthotopic heart transplantation. We present two cases of cardiogenic shock that were successfully bridged with an Impella 5.5 (Abiomed). The management enabled the patients to recover from reversible cardiointestinal syndrome and undergo successful definitive therapies.
No takes yet. Share an insight, caveat, or question.
Armas et al. (2022) conducted a case report in Refractory cardiogenic shock and cardiointestinal syndrome (n=2). Impella 5.5 was evaluated on Recovery from reversible cardiointestinal syndrome and successful definitive therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: